BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 27170998)

  • 21. Macrophage inhibitory cytokine 1 (MIC-1/GDF15) as a novel diagnostic serum biomarker in pancreatic ductal adenocarcinoma.
    Wang X; Li Y; Tian H; Qi J; Li M; Fu C; Wu F; Wang Y; Cheng D; Zhao W; Zhang C; Wang T; Rao J; Zhang W
    BMC Cancer; 2014 Aug; 14():578. PubMed ID: 25106741
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The diagnostic role of the neutrophil-to-lymphocyte ratio in predicting pancreatic ductal adenocarcinoma in patients with pancreatic diseases.
    Arima K; Okabe H; Hashimoto D; Chikamoto A; Tsuji A; Yamamura K; Kitano Y; Inoue R; Kaida T; Higashi T; Taki K; Imai K; Komohara Y; Beppu T; Takeya M; Baba H
    Int J Clin Oncol; 2016 Oct; 21(5):940-945. PubMed ID: 27023215
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CA19-9 on Postoperative Surveillance in Pancreatic Ductal Adenocarcinoma: Predicting Recurrence and Changing Prognosis over Time.
    Rieser CJ; Zenati M; Hamad A; Al Abbas AI; Bahary N; Zureikat AH; Zeh HJ; Hogg ME
    Ann Surg Oncol; 2018 Nov; 25(12):3483-3491. PubMed ID: 29786131
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum fibrinogen as a diagnostic and prognostic biomarker for pancreatic ductal adenocarcinoma.
    Chung KH; Lee JC; Lee J; Cho IK; Kim J; Jang W; Yoo BC; Hwang JH
    Pancreatology; 2020 Oct; 20(7):1465-1471. PubMed ID: 32873483
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Utility of serum CA19-9 levels in the diagnosis of pancreatic ductal adenocarcinoma in an endoscopic ultrasound referral population.
    Parikh DA; Durbin-Johnson B; Urayama S
    J Gastrointest Cancer; 2014 Mar; 45(1):74-9. PubMed ID: 24272911
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Levels of Tumor Markers in Pancreatic Neuroendocrine Carcinoma and Their Values in Differentiation Between Pancreatic Neuroendocrine Carcinoma and Pancreatic Ductal Adenocarcinoma.
    Zhuge X; Guo C; Chen Y; Feng L; Jia R; Zhao Y; Sun K; Wang Z; Chen X
    Pancreas; 2018; 47(10):1290-1295. PubMed ID: 30308534
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Downregulation of miR-124 predicts poor prognosis in pancreatic ductal adenocarcinoma patients.
    Sun B; Liu X; Gao Y; Li L; Dong Z
    Br J Biomed Sci; 2016 Oct; 73(4):152-157. PubMed ID: 27922430
    [TBL] [Abstract][Full Text] [Related]  

  • 28. miRNA-21 and miRNA-34a Are Potential Minimally Invasive Biomarkers for the Diagnosis of Pancreatic Ductal Adenocarcinoma.
    Alemar B; Izetti P; Gregório C; Macedo GS; Castro MA; Osvaldt AB; Matte U; Ashton-Prolla P
    Pancreas; 2016 Jan; 45(1):84-92. PubMed ID: 26262588
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of a novel serum biomarker for pancreatic cancer, C4b-binding protein α-chain (C4BPA) by quantitative proteomic analysis using tandem mass tags.
    Sogawa K; Takano S; Iida F; Satoh M; Tsuchida S; Kawashima Y; Yoshitomi H; Sanda A; Kodera Y; Takizawa H; Mikata R; Ohtsuka M; Shimizu H; Miyazaki M; Yokosuka O; Nomura F
    Br J Cancer; 2016 Oct; 115(8):949-956. PubMed ID: 27657339
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
    Distler M; Pilarsky E; Kersting S; Grützmann R
    Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Validation of four candidate pancreatic cancer serological biomarkers that improve the performance of CA19.9.
    Makawita S; Dimitromanolakis A; Soosaipillai A; Soleas I; Chan A; Gallinger S; Haun RS; Blasutig IM; Diamandis EP
    BMC Cancer; 2013 Sep; 13():404. PubMed ID: 24007603
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic relevance of lactate dehydrogenase in advanced pancreatic ductal adenocarcinoma patients.
    Xiao Y; Chen W; Xie Z; Shao Z; Xie H; Qin G; Zhao N
    BMC Cancer; 2017 Jan; 17(1):25. PubMed ID: 28056913
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum biomarker panels for the detection of pancreatic cancer.
    Brand RE; Nolen BM; Zeh HJ; Allen PJ; Eloubeidi MA; Goldberg M; Elton E; Arnoletti JP; Christein JD; Vickers SM; Langmead CJ; Landsittel DP; Whitcomb DC; Grizzle WE; Lokshin AE
    Clin Cancer Res; 2011 Feb; 17(4):805-16. PubMed ID: 21325298
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum CA19-9, cathepsin D, and matrix metalloproteinase-7 as a diagnostic panel for pancreatic ductal adenocarcinoma.
    Park HD; Kang ES; Kim JW; Lee KT; Lee KH; Park YS; Park JO; Lee J; Heo JS; Choi SH; Choi DW; Kim S; Lee JK; Lee SY
    Proteomics; 2012 Dec; 12(23-24):3590-7. PubMed ID: 23065739
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dysbindin as a novel biomarker for pancreatic ductal adenocarcinoma identified by proteomic profiling.
    Guo X; Lv X; Fang C; Lv X; Wang F; Wang D; Zhao J; Ma Y; Xue Y; Bai Q; Yao X; Chen Y
    Int J Cancer; 2016 Oct; 139(8):1821-9. PubMed ID: 27281120
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A review of lifestyle, metabolic risk factors, and blood-based biomarkers for early diagnosis of pancreatic ductal adenocarcinoma.
    Pang Y; Holmes MV; Chen Z; Kartsonaki C
    J Gastroenterol Hepatol; 2019 Feb; 34(2):330-345. PubMed ID: 30550622
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preoperative Serum Thymidine Kinase Activity as Novel Monitoring, Prognostic, and Predictive Biomarker in Pancreatic Cancer.
    Felix K; Hinz U; Dobiasch S; Hackert T; Bergmann F; Neumüller M; Gronowitz S; Bergqvist M; Strobel O
    Pancreas; 2018 Jan; 47(1):72-79. PubMed ID: 29189449
    [TBL] [Abstract][Full Text] [Related]  

  • 38. THBS2/CA19-9 Detecting Pancreatic Ductal Adenocarcinoma at Diagnosis Underperforms in Prediagnostic Detection: Implications for Biomarker Advancement.
    Udgata S; Takenaka N; Bamlet WR; Oberg AL; Yee SS; Carpenter EL; Herman D; Kim J; Petersen GM; Zaret KS
    Cancer Prev Res (Phila); 2021 Feb; 14(2):223-232. PubMed ID: 33067248
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lower plasma levels of glucose-dependent insulinotropic peptide (GIP) and pancreatic polypeptide (PP) in patients with ductal adenocarcinoma of the pancreas and their relation to the presence of impaired glucoregulation and weight loss.
    Škrha J; Bušek P; Uhrová J; Hrabal P; Kmochová K; Laclav M; Bunganič B; Frič P
    Pancreatology; 2017; 17(1):89-94. PubMed ID: 28027898
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of circulating MMP-9, TIMP-1 and CA19-9 in the detection of pancreatic cancer.
    Joergensen MT; Brünner N; De Muckadell OB
    Anticancer Res; 2010 Feb; 30(2):587-92. PubMed ID: 20332475
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.